KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells

por Etchin, J, Berezovskaya, A, Conway, A S, Galinsky, I A, Stone, R M, Baloglu, E, Senapedis, W, Landesman, Y, Kauffman, M, Shacham, S, Wang, J C Y, Look, A T
Publicado 2017

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

por Etchin, J, Sun, Q, Kentsis, A, Farmer, A, Zhang, Z C, Sanda, T, Mansour, M R, Barcelo, C, McCauley, D, Kauffman, M, Shacham, S, Christie, A L, Kung, A L, Rodig, S J, Chook, Y M, Look, A T
Publicado 2013

P1429: MULTIPLEX DELETION OF MYELOID ANTIGENS CD33 AND CLL-1 BY CRISPR/CAS9 IN HUMAN HEMATOPOIETIC STEM CELLS HIGHLIGHTS THE POTENTIAL OF NEXT-GENERATION TRANSPLANTS FOR AML TREATM...

por Xavier-Ferrucio, J., Luo, C., Angelini, G., Krishnamurthy, S., Patel, N., Pettiglio, M., Collingsworth, T., Isik, M., Ghodssi, A., Halfond, A., Etchin, J., Keschner, Y., Mundelboim, G., Tavares, P., Cummins, C., Falla, A., Hazelbaker, D., Paik, E., Sanchez, J., Ge, G., Lydeard, J., Lin, M. I., Chakraborty, T.
Publicado 2022